Genaera stops enrolling in Phase llb study.(Genaera Corp.)(Brief Article)

In order to conserve capital for other development programs, Genaera Corp. said it intends to stop enrolling its Phase lib trial of squalamine in non-small-cell lung cancer patients. Designed to include 90 patients, enrollment will end at the current 40 patients, Roy Levitt, Genaera's president and CEO, said. "Stopping this program at 40 patients will allow …